Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study of Relatlimab and Nivolumab for Children and Young Adults with Recurrent or Refractory Hodgkin and Non-Hodgkin Lymphoma

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying two types of blood cancers: Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma. These are conditions where the body's lymphatic system, which is part of the immune system, develops cancerous cells. The study is testing a combination of two medications, Relatlimab and Nivolumab, to see how safe and effective they are for treating these cancers in children and young adults. Relatlimab is given as an injection, while Nivolumab is provided as an infusion, both administered directly into the bloodstream.

The purpose of the study is to understand how well these medications work together and how the body handles them. Participants will receive the treatment and be monitored for any side effects and how their cancer responds. The study is divided into two parts: the first part focuses on children under 18 years old to determine the safest dose, and the second part includes young adults up to 30 years old to assess how well the treatment works based on the findings from the first part.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and the progress of their treatment. The goal is to find a new, effective treatment option for those whose cancer has returned or not responded to standard therapies. This study is an important step in exploring new ways to help young patients with these challenging conditions.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, participants will undergo an initial assessment to confirm eligibility. This includes reviewing medical history and current health status.

    Participants must have recurrent or refractory classical Hodgkin lymphoma or non-Hodgkin lymphoma and meet specific criteria related to previous treatments and disease state.

  2. Step 2

    Treatment administration

    Participants will receive two medications: relatlimab and nivolumab. Both are administered through an intravenous infusion, which means they are given directly into a vein.

    The dosage and frequency of administration will be determined based on the study's phase and the participant's specific needs. The treatment aims to evaluate safety and effectiveness.

  3. Step 3

    Monitoring and follow-up

    Participants will be closely monitored for any side effects or adverse reactions. Regular check-ups and tests will be conducted to assess the body's response to the treatment.

    The study will track various health indicators, including the maximum concentration of the medication in the blood and the overall response rate to the treatment.

  4. Step 4

    Completion and evaluation

    At the end of the treatment period, participants will undergo a final evaluation to determine the treatment's effectiveness and any long-term effects.

    The study aims to gather comprehensive data on the safety and potential benefits of the medication combination for future treatment considerations.

Who can join the trial?

14 criteria

  • Participants must be **male or female**.
  • Participants must be **less than 18 years old** for Part A of the study, and **30 years old or younger** for Part B.
  • Participants must have **Recurrent or Refractory Classical Hodgkin Lymphoma (R/R cHL)** or **Non-Hodgkin Lymphoma (NHL)**. "Recurrent" means the disease has come back after treatment, and "Refractory" means the disease did not respond to treatment.
  • Participants must have a **confirmed diagnosis** of high-risk R/R cHL or R/R NHL after not responding to or failing one or more standard treatments.
  • Participants with R/R NHL may include those with specific types of lymphoma such as:
    • Primary mediastinal B-cell lymphoma
    • Diffuse large B-cell lymphoma (DLBCL)
    • Mediastinal gray zone lymphoma (MGZL)
    • Anaplastic large cell lymphoma (ALCL)
    • Burkitt lymphoma (with less than 25% malignant cells)
    • Lymphoblastic lymphoma (with less than 25% of marrow cells being cancerous)
    • NK/T-cell lymphoma (excluding aggressive subtypes)
    • Peripheral T-cell lymphoma (PTCL)
    • The participant's current disease must be **resistant to standard therapy**.
    • Participants must have **measurable disease** that is **PET positive**. This means the disease can be seen on a PET scan, a type of imaging test.

Who cannot join the trial?

9 criteria

  • Patients who have a different type of cancer than the ones being studied cannot participate.
  • Patients who have had a severe allergic reaction to similar medications in the past are not eligible.
  • Patients who are currently taking other medications that might interfere with the study treatment cannot join.
  • Patients with uncontrolled infections or other serious illnesses are not allowed to participate.
  • Patients who are pregnant or breastfeeding cannot take part in the study.
  • Patients who have received certain treatments recently, such as chemotherapy or radiation, may not be eligible.
  • Patients with certain heart conditions or other significant health issues might be excluded.
  • Patients who have participated in another clinical trial recently may not be eligible.
  • Patients who are unable to follow the study procedures or attend the required visits cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Relatlimab

    is a type of medication known as an immune checkpoint inhibitor. It works by helping the body's immune system recognize and attack cancer cells more effectively. In this trial, it is being tested in combination with another medication to see if it can help treat certain types of lymphoma, which are cancers of the lymphatic system.

  • Nivolumab

    is another immune checkpoint inhibitor. It helps the immune system fight cancer by blocking a protein that prevents immune cells from attacking cancer cells. In this study, it is used together with Relatlimab to see if the combination can improve treatment outcomes for young patients with specific types of lymphoma.

What is already known about the treatment

  • Relatlimab

    Relatlimab is administered through an intravenous infusion, meaning it is given directly into the bloodstream through a vein. It is currently being studied in clinical trials for its potential use in treating recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma, particularly in pediatric and young adult patients. The medication works by targeting and blocking a specific protein on immune cells, which helps the body's immune system recognize and attack cancer cells more effectively. Relatlimab is classified as an immune checkpoint inhibitor, a type of drug that helps to boost the immune response against cancer.

  • Nivolumab

    Nivolumab is also administered via intravenous infusion, allowing it to enter the bloodstream directly. It is being investigated in combination with relatlimab for its effectiveness in treating recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma in younger patients. Nivolumab functions by inhibiting a protein that normally suppresses the immune system, thereby enhancing the body's ability to fight cancer cells. It belongs to the pharmacological class of immune checkpoint inhibitors, which are designed to strengthen the immune system's response to cancer.

Investigated diseases

  • Classical Hodgkin Lymphoma

    Classical Hodgkin Lymphoma is a type of cancer that originates in the lymphatic system, which is part of the immune system. It is characterized by the presence of Reed-Sternberg cells, a specific type of abnormal cell. The disease often begins in the lymph nodes and can spread to other parts of the body, including the spleen, liver, and bone marrow. Symptoms may include painless swelling of lymph nodes, fever, night sweats, and weight loss. As the disease progresses, it can affect the body's ability to fight infections. The progression can vary, with some cases remaining localized while others spread more extensively.

  • Non-Hodgkin Lymphoma

    Non-Hodgkin Lymphoma is a diverse group of blood cancers that develop in the lymphatic system. Unlike Hodgkin Lymphoma, it does not involve Reed-Sternberg cells. The disease can start in various types of white blood cells and can occur in lymph nodes or other lymphatic tissues. Symptoms may include swollen lymph nodes, fever, night sweats, and unexplained weight loss. The progression of Non-Hodgkin Lymphoma can vary widely, with some forms being slow-growing and others being more aggressive. It can spread to other parts of the body, including the liver, bone marrow, and spleen.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2023-503715-14-00Protocol codeCA224-069Estimated enrolment99 patientsSponsorBristol Myers Squibb International Corporation

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).